260 related articles for article (PubMed ID: 11023670)
1. Constitutive expression of IL-6-LIKE cytokines in normal bone marrow: implications for pathophysiology of myeloma.
Barton BE; Murphy TF
Cytokine; 2000 Oct; 12(10):1537-45. PubMed ID: 11023670
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
3. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
4. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
5. [Mechanisms of multiple myeloma cell growth].
Simizu S; Konda S
Rinsho Ketsueki; 1993 Apr; 34(4):418-22. PubMed ID: 8510327
[TBL] [Abstract][Full Text] [Related]
6. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha.
Haynesworth SE; Baber MA; Caplan AI
J Cell Physiol; 1996 Mar; 166(3):585-92. PubMed ID: 8600162
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6): relationship to osteopenia with enhanced adipogenesis.
Kodama Y; Takeuchi Y; Suzawa M; Fukumoto S; Murayama H; Yamato H; Fujita T; Kurokawa T; Matsumoto T
J Bone Miner Res; 1998 Sep; 13(9):1370-7. PubMed ID: 9738508
[TBL] [Abstract][Full Text] [Related]
8. Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen.
Barton BE; Murphy TF
Cytokine; 2001 Dec; 16(6):251-7. PubMed ID: 11884029
[TBL] [Abstract][Full Text] [Related]
9. Expression and production of interleukin 10 in human myeloma cell lines.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A
Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145
[TBL] [Abstract][Full Text] [Related]
10. Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma.
Liu S; Ishikawa H; Li FJ; Ma Z; Otsuyama K; Asaoku H; Abroun S; Zheng X; Tsuyama N; Obata M; Kawano MM
Cancer Res; 2005 Mar; 65(6):2269-76. PubMed ID: 15781640
[TBL] [Abstract][Full Text] [Related]
11. Role of mitogen-activated protein kinase family in serum-induced leukaemia inhibitory factor and interleukin-6 secretion by bone marrow stromal cells.
Nakao T; Kim S; Ohta K; Kawano H; Hino M; Miura K; Tatsumi N; Iwao H
Br J Pharmacol; 2002 Aug; 136(7):975-84. PubMed ID: 12145097
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
[TBL] [Abstract][Full Text] [Related]
13. Modulation of expression of the anti-inflammatory cytokines interleukin-13 and interleukin-10 by interleukin-3.
Marietta EV; Chen Y; Weis JH
Eur J Immunol; 1996 Jan; 26(1):49-56. PubMed ID: 8566083
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
[TBL] [Abstract][Full Text] [Related]
15. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
16. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
[TBL] [Abstract][Full Text] [Related]
17. Effects of lipid mediators on the synthesis of leukaemia inhibitory factor and interleukin 6 by human bone marrow stromal cells.
Denizot Y; Trimoreau F; Praloran V
Cytokine; 1998 Oct; 10(10):781-5. PubMed ID: 9811531
[TBL] [Abstract][Full Text] [Related]
18. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
[TBL] [Abstract][Full Text] [Related]
19. Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells.
Chauhan D; Uchiyama H; Urashima M; Yamamoto K; Anderson KC
Stem Cells; 1995 Aug; 13 Suppl 2():35-9. PubMed ID: 8520509
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
